What is the 13F Pro Quality Score for BRNS?

13F Pro ranks Barinthus Biotherapeutics plc. (BRNS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BRNS's current score at https://13fpro.ai/research/BRNS (free sign-up required for the full ranking).

Which hedge funds own the most BRNS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BRNS include M&G Plc, SC CHINA HOLDING Ltd, GLR Partners,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BRNS as soon as new 13F filings post.

Where does 13F Pro source BRNS data?

All Barinthus Biotherapeutics plc. fundamentals and ownership data come directly from SEC EDGAR. Barinthus Biotherapeutics plc. files with the SEC under CIK 1828185. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BRNS in?

Barinthus Biotherapeutics plc. (BRNS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BRNS research updated on 13F Pro?

BRNS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Barinthus Biotherapeutics plc.(BRNS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1828185 BRNS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 14 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BRNS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Barinthus Biotherapeutics plc. (BRNS), a Healthcare sector company. BRNS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 14 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Barinthus Biotherapeutics plc. reports net income of $-5.5M, free cash flow of $-3.4M. Top institutional holders of BRNS by reported 13-F value include M&G Plc, SC CHINA HOLDING Ltd, GLR Partners,, based on the most recent SEC filings. BRNS trades on the Nasdaq exchange and files with the SEC under CIK 1828185. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BRNS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Barinthus Biotherapeutics plc. directly from SEC EDGAR.

Net Income

Q1 2026

$-5.5M

Free Cash Flow

Q1 2026

$-3.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-66.5% YoY

$15.0MFY 2024

FY21 $268.0KFY22 $44.7MFY24 $15.0M

Net Income

-1243.3% YoY

$-61.1MFY 2024

FY21 $-50.9MFY22 $5.3MFY24 $-61.1M

Operating Income

-1582.0% YoY

$-68.0MFY 2024

FY21 $-45.2MFY22 $-4.0MFY24 $-68.0M

EPS (Diluted)

-1207.1% YoY

$-1.55FY 2024

FY21 $-1.96FY22 $0.14FY24 $-1.55

Total Assets

-40.7% YoY

$160.3MFY 2024

FY21 $280.7MFY22 $270.2MFY24 $160.3M

Total Debt

—FY 2024

FY21 $159.0KFY22 —FY24 —

Op. Cash Flow

-100.5% YoY

$-28.9MFY 2024

FY21 $-32.6MFY22 $-14.4MFY24 $-28.9M

Metric	FY 2024	FY 2022	FY 2021
Revenue	$15.0M -66.5%	$44.7M +16580.2%	$268.0K
Net Income	$-61.1M -1243.3%	$5.3M +110.5%	$-50.9M
Operating Income	$-68.0M -1582.0%	$-4.0M +91.1%	$-45.2M
EPS (Diluted)	$-1.55 -1207.1%	$0.14 +107.1%	$-1.96
Total Assets	$160.3M -40.7%	$270.2M -3.7%	$280.7M
Total Debt	—	—	$159.0K
Operating Cash Flow	$-28.9M -100.5%	$-14.4M +55.7%	$-32.6M

AI Insight: BRNS Financial Trends

Barinthus is burning through equity rapidly — down from $157M to $66M in seven quarters — though quarterly cash consumption is decelerating meaningfully.

• Equity has eroded from $157M in Q2 2024 to $66M in Q1 2026, a cumulative decline of $91M over seven quarters.

• Operating cash outflow has improved from -$18M in Q3 2024 to -$3M in Q1 2026, suggesting meaningful burn-rate deceleration.

• Net loss narrowed from -$21M in Q2 2025 to -$6M in Q1 2026, the lowest quarterly loss in the observable period.

• Revenue is absent in six of eight quarters; the sole $15M quarter (Q3 2024) appears non-recurring with no follow-through.

⚠ Equity at $66M in Q1 2026 versus ~$6M quarterly burn — runway is critically short without new capital or revenue.

⚠ Whether the burn deceleration in Q4 2025–Q1 2026 reflects structural cost cuts or temporary timing warrants close monitoring.

⚠ No debt is reported across all periods; watch for any new borrowings that could signal liquidity stress.

AI Insight: BRNS Ratio Trends

BRNS remains deeply loss-making, but return metrics show tentative improvement in Q1 2026 — still far from profitability.

• ROE improved from -82.5% in Q2 2025 to -33.3% in Q1 2026, the least negative reading in the visible dataset.

• ROA recovered from a trough of -65.2% in Q2 2025 to -24.0% in Q1 2026, a meaningful directional improvement.

• ROIC remains deeply negative at -36.6% in Q1 2026, though down sharply from the -91.1% trough in Q2 2025.

⚠ TTM ROE of -78.8% and ROIC of -84.4% signal the trailing annual burn is far worse than the latest single quarter implies.

⚠ OpMargin and NPM data are almost entirely absent; without them, the true earnings trajectory cannot be confirmed.

⚠ D/E is missing across all periods — leverage and balance-sheet stress cannot be assessed from available data.

Get alerted when BRNS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Barinthus Biotherapeutics plc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BRNS

M&G Plc
$5.2M5,197,349 sh
SC CHINA HOLDING Ltd
$1.2M1,420,473 sh
GLR Partners, LLC
$707.5K1,243,377 sh
DC Funds, LP
$365.4K642,204 sh
Rangeley Capital, LLC
$90.7K159,465 sh
RENAISSANCE TECHNOLOGIES LLC
$85.9K151,000 sh
Johns Hopkins University
$69.6K122,237 sh
CITADEL ADVISORS LLC
$68.1K118,996 sh
Baird Financial Group, Inc.
$60.3K105,961 sh
GTS SECURITIES LLC
$41.9K73,210 sh

Fund	Value	Shares
M&G Plc	$5.2M	5,197,349
SC CHINA HOLDING Ltd	$1.2M	1,420,473
GLR Partners, LLC	$707.5K	1,243,377
DC Funds, LP	$365.4K	642,204
Rangeley Capital, LLC	$90.7K	159,465
RENAISSANCE TECHNOLOGIES LLC	$85.9K	151,000
Johns Hopkins University	$69.6K	122,237
CITADEL ADVISORS LLC	$68.1K	118,996
Baird Financial Group, Inc.	$60.3K	105,961
GTS SECURITIES LLC	$41.9K	73,210

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BRNS on your watchlist

Track score changes the day Barinthus Biotherapeutics plc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BRNS a good stock to buy?

13F Pro's AI-powered analysis of Barinthus Biotherapeutics plc. (BRNS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BRNS are available on the BRNS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BRNS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BRNS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Barinthus Biotherapeutics plc.'s investment landscape.